CATO 佳途CATO · CNAS + ANAB ISO 17034 双体系认可标准物质生产者CNAS + ANAB ISO 17034 dual-accredited reference material producer
销售顾问Sales contact 卢振明Kaka Lu+86 185 2048 1969kaka@cato-chem.com
Exemestane

依西美坦 杂质对照品Exemestane Impurities

EP28 个杂质条目28 impurity entries

本页汇总 依西美坦 的 28 个杂质对照品条目,其中药典杂质标注了 EP/USP 编号。杂质谱是仿制药杂质研究、方法开发与稳定性考察的起点——先锁定品种,再逐条比对结构差异与保留行为。This page collects 28 impurity reference standards of Exemestane with EP/USP numbering where applicable. The impurity profile is the starting point for related-substance method development, forced degradation and stability studies.

批量索取报价 / COABulk quote / COA在全站目录中检索Search the full catalogue

相关研究文献Related literature

以下为 依西美坦(Exemestane)在公开文献中的研究报道(题录信息,来源 PubMed),供方法开发与文献调研参考。Selected peer-reviewed publications on this drug substance — bibliographic records from PubMed.

  1. 杂质研究Impurity studiesDevelopment and validation of a stability indicating LC method for the assay and related substances determination of exemestane, an aromatase inhibitor
    Journal of pharmaceutical and biomedical analysis · 2009 · Suresh Kumar R et al.  ·  PMID 19595529  ·  DOI
  2. 杂质研究Impurity studiesDevelopment and Validation of a Robust RP-HPLC Method for the Simultaneous Analysis of Exemestane and Thymoquinone and Its Application to Lipid-Based Nanoformulations
    ACS omega · 2024 · Gupta P et al.  ·  PMID 39035924  ·  DOI
  3. 杂质研究Impurity studiesUse of the hyphenated LC-MS/MS technique and NMR/IR spectroscopy for the identification of exemestane stress degradation products during the drug development
    European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences · 2017 · Stolarczyk EU et al.  ·  PMID 28865686  ·  DOI
  4. 杂质研究Impurity studiesDevelopment and validation of stability indicating method for the determination of exemestane by reverse phase high performance liquid chromatography
    Journal of chromatographic science · 2011 · Konda B et al.  ·  PMID 21859539  ·  DOI

合成路线参考Reported synthetic routes

以下为公开文献中报道的合成方法(题录信息)。标题多已点明关键反应,可据此查阅原文了解完整路线与工艺条件。Published synthetic approaches. Titles usually name the key transformation; consult the original articles for full routes.

  • 合成方法SynthesisSynthesis of exemestane labelled with (13)C
    Steroids · 2008 · Fontana E et al.  ·  PMID 18423505  ·  DOI

依西美坦 —— 原料药与杂质对照品Exemestane — drug substance & impurities

共 28 个条目(含原料药本体)28 items incl. the drug substance
Exemestane Impurity 12 (Exemestane EP Impurity B) structure
EPB
依西美坦杂质12(依西美坦EP杂质B)Exemestane Impurity 12 (Exemestane EP Impurity B)
Exemestane Impurity 12 (Exemestane EP Impurity B)
CAS No.184972-09-6
Chemical FormulaC20H26O3
Purity>95%询价On request
10mg25mg50mg100mg
Exemestane Impurity 24 (Exemestane EP Impurity C) structure
EPC
依西美坦杂质24(依西美坦EP杂质C)Exemestane Impurity 24 (Exemestane EP Impurity C)
Exemestane Impurity 24 (Exemestane EP Impurity C)
CAS No.2130745-60-5
Chemical FormulaC21H24O2
Purity>95%询价On request
10mg25mg50mg100mg
Exemestane Impurity 15 (Exemestane EP Impurity E) structure
EPE
依西美坦杂质15(依西美坦EP杂质E)Exemestane Impurity 15 (Exemestane EP Impurity E)
Exemestane Impurity 15 (Exemestane EP Impurity E)
CAS No.19457-55-7
Chemical FormulaC20H26O2
Purity>95%询价On request
10mg25mg50mg100mg
Exemestane Impurity 22 (Exemestane EP Impurity F) structure
EPF
依西美坦杂质22(依西美坦EP杂质F)Exemestane Impurity 22 (Exemestane EP Impurity F)
Exemestane Impurity 22 (Exemestane EP Impurity F)
CAS No.72648-46-5
Chemical FormulaC19H22O3
Purity>95%询价On request
10mg25mg50mg100mg
Exemestane Impurity 23 (Exemestane EP Impurity H) structure
EPH
依西美坦杂质23(依西美坦EP杂质H)Exemestane Impurity 23 (Exemestane EP Impurity H)
Exemestane Impurity 23 (Exemestane EP Impurity H)
CAS No.122370-91-6
Chemical FormulaC20H26O2
Purity>95%询价On request
10mg25mg50mg100mg
Exemestane Impurity 7 (Exemestane EP Impurity J) structure
EPJ
依西美坦杂质7(依西美坦EP杂质J)Exemestane Impurity 7 (Exemestane EP Impurity J)
Exemestane Impurity 7 (Exemestane EP Impurity J)
CAS No.1160599-91-6
Chemical FormulaC22H28O3
Purity>95%询价On request
10mg25mg50mg100mg
Exemestane Impurity 3 structure
3
依西美坦杂质3Exemestane Impurity 3
Exemestane Impurity 3
CAS No.152764-31-3
Chemical FormulaC20H24O3
Purity>95%询价On request
10mg25mg50mg100mg
Exemestane Impurity 4 structure
4
依西美坦杂质4Exemestane Impurity 4
Exemestane Impurity 4
CAS No.152764-24-4
Chemical FormulaC20H24O3
Purity>95%询价On request
10mg25mg50mg100mg
Exemestane Impurity 11 structure
11
依西美坦杂质11Exemestane Impurity 11
Exemestane Impurity 11
CAS No.159354-61-7
Chemical FormulaC20H24O3
Purity>95%询价On request
10mg25mg50mg100mg
Exemestane Impurity 13 structure
13
依西美坦杂质13Exemestane Impurity 13
Exemestane Impurity 13
CAS No.861395-77-9
Chemical FormulaC21H28O5S
Purity>95%询价On request
10mg25mg50mg100mg
Exemestane Impurity 14 structure
14
依西美坦杂质14Exemestane Impurity 14
Exemestane Impurity 14
CAS No.881896-95-3
Chemical FormulaC21H28O3
Purity>95%询价On request
10mg25mg50mg100mg
Exemestane Impurity 16 structure
16
依西美坦杂质16Exemestane Impurity 16
Exemestane Impurity 16
CAS No.933455-73-3
Chemical FormulaC21H28O3
Purity>95%询价On request
10mg25mg50mg100mg
Exemestane Impurity 17 structure
17
依西美坦杂质17Exemestane Impurity 17
Exemestane Impurity 17
CAS No.10104-53-7
Chemical FormulaC19H24O3
Purity>95%现货In stock
10mg25mg50mg100mg
Exemestane Impurity 25 structure
25
依西美坦杂质25Exemestane Impurity 25
Exemestane Impurity 25
CAS No.2467590-81-2
Chemical FormulaC20H24O2
Purity>95%询价On request
10mg25mg50mg100mg
Exemestane Impurity 31 structure
31
依西美坦杂质31Exemestane Impurity 31
Exemestane Impurity 31
CAS No.184972-12-1
Chemical FormulaC20H24O3
Purity>95%询价On request
10mg25mg50mg100mg
Exemestane Impurity 32 structure
32
依西美坦杂质32Exemestane Impurity 32
Exemestane Impurity 32
CAS No.107868-36-0
Chemical FormulaC20H23ClO2
Purity>95%询价On request
10mg25mg50mg100mg
Exemestane Impurity 33 structure
33
依西美坦杂质33Exemestane Impurity 33
Exemestane Impurity 33
CAS No.152764-29-9
Chemical FormulaC20H26O3
Purity>95%询价On request
10mg25mg50mg100mg
Exemestane Impurity 36 structure
36
依西美坦杂质36Exemestane Impurity 36
Exemestane Impurity 36
CAS No.1331732-05-8
Chemical FormulaC20H26O3
Purity>95%询价On request
10mg25mg50mg100mg
Exemestane Impurity 39 structure
39
依西美坦杂质39Exemestane Impurity 39
Exemestane Impurity 39
CAS No.152764-26-6
Chemical FormulaC20H24O3
Purity>95%询价On request
10mg25mg50mg100mg
Exemestane Impurity 41 structure
41
依西美坦杂质41Exemestane Impurity 41
Exemestane Impurity 41
CAS No.184972-11-0
Chemical FormulaC20H26O4
Purity>95%询价On request
10mg25mg50mg100mg
Exemestane Impurity 45 structure
45
依西美坦杂质45Exemestane Impurity 45
Exemestane Impurity 45
CAS No.3347-73-7
Chemical FormulaC20H28O2
Purity>95%询价On request
10mg25mg50mg100mg
Exemestane Impurity 47 structure
47
依西美坦杂质47Exemestane Impurity 47
Exemestane Impurity 47
CAS No.121021-51-0
Chemical FormulaC20H26O3
Purity>95%询价On request
10mg25mg50mg100mg
Exemestane Impurity 48 structure
48
依西美坦杂质48Exemestane Impurity 48
Exemestane Impurity 48
CAS No.80108-48-1
Chemical FormulaC20H26O2
Purity>95%询价On request
10mg25mg50mg100mg
Exemestane Impurity 49 structure
49
依西美坦杂质49Exemestane Impurity 49
Exemestane Impurity 49
CAS No.1309048-76-7
Chemical FormulaC26H34O8
Purity>95%询价On request
10mg25mg50mg100mg
Exemestane Impurity 50 structure
50
依西美坦杂质50Exemestane Impurity 50
Exemestane Impurity 50
CAS No.2268001-09-6
Chemical FormulaC26H34O8
Purity>95%询价On request
10mg25mg50mg100mg
Exemestane Impurity 52 structure
52
依西美坦杂质52Exemestane Impurity 52
Exemestane Impurity 52
CAS No.1035-69-4
Chemical FormulaC19H24O2
Purity>95%询价On request
10mg25mg50mg100mg
Exemestane Impurity 53 structure
53
依西美坦杂质53Exemestane Impurity 53
Exemestane Impurity 53
CAS No.1420-49-1
Chemical FormulaC19H24O2
Purity>95%询价On request
10mg25mg50mg100mg
Exemestane Impurity 54 structure
54
依西美坦杂质54Exemestane Impurity 54
Exemestane Impurity 54
CAS No.633-35-2
Chemical FormulaC19H22O2
Purity>95%询价On request
10mg25mg50mg100mg

结构式清晰度以随货 COA 与厂家图谱为准;目录之外的杂质可按需定制合成或调取。Structural confirmation is governed by the COA and manufacturer spectra. Impurities outside this list can be custom-synthesised or sourced on request.

Literature & synthesis

依西美坦 —— 研究文献与合成路线Exemestane — literature & synthetic routes

以下题录由公开学术数据库按品种名检索汇总,供 依西美坦 的杂质谱研究、分析方法开发与工艺路线选择参考。文献题名与专利标题均可点击查看原文,版权归原作者与出版方所有。Citations below are aggregated from public scholarly databases by drug-substance name, for reference in impurity profiling, analytical method development and route selection for Exemestane. Titles link to the original records; copyright remains with the authors and publishers.

杂质与降解研究文献Impurity & degradation studies

  1. Development and validation of a stability indicating LC method for the assay and related substances determination of exemestane, an aromatase inhibitor
    Suresh Kumar R, Narasimha Naidu M, Srinivasulu K, et al. · Journal of pharmaceutical and biomedical analysis · 2009 · 被引 3cited 3
  2. Development and validation of stability indicating method for the determination of exemestane by reverse phase high performance liquid chromatography
    Konda B, Tiwari RN, Fegade H · Journal of chromatographic science · 2011 · 被引 3cited 3
  3. Use of the hyphenated LC-MS/MS technique and NMR/IR spectroscopy for the identification of exemestane stress degradation products during the drug development
    Stolarczyk EU, Rosa A, Kubiszewski M, et al. · European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences · 2017 · 被引 7cited 7
  4. Development and Method Validation of Design of Experiments-Optimized Tablet Formulation for Simultaneous Detection of Exemestane and Everolimus
    Kumar A, Kurmi BD, Singh D, et al. · Assay and drug development technologies · 2023

合成与制备工艺专利Synthesis & process patents

  1. PROCESS FOR THE PREPARATION OF EXEMESTANE
    AGGARWAL ASHVIN KUMAR, JAIN ANSHUL KUMAR, CHIDAMBARAM VENKATESWARAN SRINIVASAN, WADHWA LALIT · 公开号 WO2010076811WO2010076811 · 2010
  2. PROCESS FOR PREPARING AROMATASE INHIBITOR EXEMESTANE
    AGARWAL VIRENDRA KUMAR, SINGH MANOJ KUMAR, PATEL ANANT M, SOLANKI KRISPALSINH · 公开号 WO2009093262WO2009093262 · 2009
  3. PROCESS FOR PREPARING AROMATIASE INHIBITOR EXEMESTANE
    AGARWAL VIRENDRA KUMAR, SINGH MANOJ KUMAR, PATEL ANANT M, SOLANKI KIRTIPALSINH · 公开号 US2010311993US2010311993 · 2010
  4. PROCESS FOR PREPARING AROMATASE INHIBITOR EXEMESTANE
    AGARWAL VIRENDRA KUMAR, SINGH MANOJ KUMAR, PATEL ANANT M, SOLANKI KIRTIPALSINH · 公开号 EP2231691EP2231691 · 2010
  5. Process for preparing anti-cancer medicine Exemestane
    ZHU QIN, PAN JUNFANG · 公开号 CN1491957CN1491957 · 2004

题录与链接来自公开数据库 Europe PMC(含 PubMed 与全球专利题录)与 WIPO PatentScope,本站仅提供索引,不转载正文;如链接失效请以数据库检索为准。Citations are indexed from public databases (Europe PMC incl. PubMed and patent records, WIPO PatentScope); we provide links only and do not reproduce full text.

For formulation & analytical R&D

依西美坦 杂质谱研究要点Exemestane — impurity profiling notes

下面这些是拿到 依西美坦 的 28 个杂质条目之后,仿制药研发最常遇到的几件事。先把杂质的来源分清,再决定要不要买对照品、买哪几个。Once you have the 28 impurity entries for Exemestane, these are the questions that come up most in generic development. Classify the source of each impurity first, then decide which reference standards you actually need.

01工艺杂质Process impurities

起始物料、中间体、副产物、催化剂与溶剂残留。多来自合成路线本身,应在工艺开发阶段用加标试验定位。Starting materials, intermediates, by-products, catalysts and residual solvents — traced back to the synthetic route and located with spiking studies during process development.

02降解杂质Degradation impurities

水解、氧化、光解、高温高湿与聚合产物。需通过强制降解试验识别,并确认方法具备稳定性指示能力。Hydrolytic, oxidative, photolytic, thermal and polymeric degradants — identified through forced degradation, with the method proven stability-indicating.

03药典杂质Pharmacopoeial impurities

EP/USP 已收载并有官方编号的杂质(如 EP Impurity A、USP Related Compound B)。申报时通常需逐项对照。Impurities already monographed with official designations (e.g. EP Impurity A, USP Related Compound B), normally compared item by item during filing.

04基因毒性杂质Genotoxic impurities

含警示结构、需按 ICH M7 进行危害评估与限度推导(TTC 1.5 µg/日)。该类杂质必须用对照品准确控制。Structurally alerting compounds requiring ICH M7 hazard assessment and limit derivation (TTC 1.5 µg/day); these must be controlled with an authentic reference standard.

05同位素标记物Isotopically labelled standards

氘代、¹³C、¹⁵N 标记的同类物,主要用作 LC-MS/MS 生物分析的内标,抵消基质效应与回收率波动。Deuterated, ¹³C- and ¹⁵N-labelled analogues used as internal standards in LC-MS/MS bioanalysis to compensate matrix effects and recovery variation.

06代谢与转化产物Metabolites & conversion products

体内代谢物、强制降解转化物与工艺中间态,常见于杂质谱比对与稳定性考察中。In-vivo metabolites, forced-degradation products and process intermediates encountered in impurity profiling and stability studies.

本品种含药典编号杂质(EP/USP)。申报时药典已收载的杂质通常需要逐项对照,建议优先备齐药典编号对照品,再补充工艺与降解杂质。This drug substance includes pharmacopoeially designated impurities (EP/USP). Monographed impurities normally need item-by-item comparison during filing, so secure the pharmacopoeial standards first, then fill in process and degradation impurities.

方法开发与对照品使用建议Method development and standards usage

先定分离,再谈定量Resolution first, then quantification

主成分与相邻杂质峰分离度应 ≥1.5;用杂质对照品确定相对保留时间与相对响应因子,避免用自身对照法掩盖响应差异。Target baseline resolution ≥1.5 between the main component and adjacent impurities; establish relative retention and relative response factors with authentic impurity standards rather than relying on self-comparison.

校正因子不可忽略Never ignore response factors

紫外吸收差异大的杂质必须校正,否则定量结果系统性偏低或偏高。EP/USP 已给出校正因子的按药典执行。Impurities with markedly different UV response need correction, otherwise results are systematically biased. Where EP/USP publish a correction factor, follow the monograph.

强制降解要做全Run the full forced-degradation panel

建议覆盖酸、碱、氧化(H₂O₂)、光照(ICH Q1B)、高温高湿;主峰纯度用二极管阵列或质谱确认。Cover acid, base, peroxide oxidation, photostability (ICH Q1B) and heat/humidity; confirm peak purity by DAD or MS.

定义报告阈值Set reporting and identification thresholds

按 ICH Q3A/Q3B 设定报告阈值、鉴定阈值与界定阈值,避免为无意义的峰投入过多工作量。Apply ICH Q3A/Q3B reporting, identification and qualification thresholds so effort is not spent on insignificant peaks.

标准品储存有讲究Store standards properly

杂质对照品多建议 −20 ℃ 避光、干燥、密封保存;溶液现配现用,并记录开瓶与配制日期。Most impurity standards should be stored at −20 °C, protected from light and moisture; prepare solutions fresh and record opening and preparation dates.

用结构式先做初判Start from the structure

先比对杂质与主成分的结构差异,可预判其保留行为、紫外响应与可能的降解路径,能显著减少试错。Comparing the impurity structure with the parent drug predicts retention behaviour, UV response and probable degradation routes, cutting trial and error.

以上为通行的杂质研究实践提示,不针对具体品种给出结论。实际限度、校正因子与色谱条件请以 EP/USP 各论及你们的验证数据为准。需要某个杂质的结构确证资料、COA 或定制合成,可直接联系我们。The above are general impurity-profiling notes and are not conclusions about this specific drug substance. Actual limits, correction factors and chromatographic conditions follow the EP/USP monograph and your own validation data. Contact us for structural confirmation data, COAs or custom synthesis.
索取杂质谱报价 / COARequest a quote / COA← 查看其它品种← Other drug substances